Neurogene Inc.
Neurogene Inc. (NGNE): 3 pipeline candidates · 1 upcoming catalyst · ~27 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
27.4 months
D/E 0.11 · 43% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~1262d
0 buys · 12 sells (180d)
A transparent, data-derived signal for Neurogene Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$457.8M
Cash
$124.5M
Quarterly Burn
$26.1M
Runway
27.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
94
Total value held
$258.7M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 1,717,127 | $34.6M |
| rtw investments, lp | 1,362,456 | $27.5M |
| vanguard capital management llc | 1,029,454 | $20.8M |
| blackrock, inc. | 1,005,070 | $20.3M |
| baker bros. advisors lp | 991,691 | $20.0M |
| balyasny asset management l.p. | 718,389 | $14.5M |
| toronto dominion bank | 681,337 | $13.7M |
| jennison associates llc | 527,685 | $10.6M |
| arrowmark colorado holdings llc | 524,796 | $10.6M |
| great point partners llc | 500,000 | $10.1M |
Showing top 10 of 94 institutional holders of Neurogene Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Neurogene Inc.'s pipeline?
Neurogene Inc. (NGNE) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neurogene Inc.'s lead drug candidate?
Neurogene Inc.'s most advanced tracked candidate is ngn-101 (Phase 3) for CLN5 Batten disease.
What is Neurogene Inc.'s next catalyst?
Neurogene Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, " — expected December 1, 2029.
What is Neurogene Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neurogene Inc. has approximately 27.4 months of cash runway.
What is Neurogene Inc.'s market capitalization?
Neurogene Inc.'s market capitalization is approximately $457.8M.
Get the full picture on Neurogene Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.